Moffitt Cancer Center | Strategic Alliance Partners

May 03, 2023

Amanda Bloomer, PhD, discusses the comparison of health-related quality of life outcomes between younger and older adult patients with newly diagnosed colorectal cancer evaluated in the ColoCare study.

May 03, 2023

Closing out their discussion on the management of cutaneous squamous cell carcinoma, expert panelists share clinical pearls and excitement for the future.

May 03, 2023

An expert panel analyzes BRAF/MEK dual inhibitor therapy for the treatment of melanoma.

May 03, 2023

Anna C. Pavlick, DO, discusses factors that impact treatment selection for patients with melanoma.

May 02, 2023

Yayi Zhao, discusses how the prevalence of existing medical conditions and clinical factors may vary by race and effect eligibility for enrollment in clinical trials in patients with cancer.

May 01, 2023

Shahrzad A. Zamani, discusses the prevalence of cancer disparities in patients with cancer in sexual and gender minority populations.

April 26, 2023

Heather Han, MD, discusses prior research with gedatolisib that provided the rationale for the phase 3 VIKTORIA-1 trial (NCT05501886) in patients with hormone receptor (HR)–positive, HER2-negative metastatic breast cancer.

April 26, 2023

Niveditha Nerlakanti, discusses the investigation of HDAC inhibitors in osteosarcoma.

April 26, 2023

Marilena Tauro, PhD, discusses the role for ULK3 in regulating autophagy in multiple myeloma.

April 26, 2023

Paul Stewart, PhD, discusses the multiomic landscape of squamous cell lung cancer.

April 26, 2023

Yiming Wu, PhD, discusses a study identifying METTL3-mediated N6-methyladenosine modification as a key translational regulator of splicing factors, and how this mechanism contributes to the progression of chronic lymphocytic leukemia.

April 26, 2023

Mostafa Nasr, PhD candidate, discusses the development of novel preclinical models of prostate cancer dormancy, and the significance of these outcomes may have on future research in metastatic prostate cancer.

April 26, 2023

Dr Vishal Patel shares a surgeon’s perspective on MDC, followed by a discussion on how intensifying treatment after surgery may improve outcomes for higher-risk patients with CSCC.

April 26, 2023

Experts in the field of CSCC revisit the concept of multidisciplinary care and consider best communication strategies.

April 26, 2023

Expert oncologists look to the future of treatment for cutaneous squamous cell carcinoma.

April 26, 2023

Skin cancer expert Anna C. Pavlick, DO, discusses treatment duration approaches for cutaneous squamous cell carcinoma.

April 25, 2023

Cassandra A. Hathaway, MD, discusses the rationale for investigating the association between distress, such as depression, and the tumor immune microenvironment in patients with ovarian cancer.

April 19, 2023

Shared insight on novel treatment modalities in the setting of cutaneous squamous cell carcinoma and how they may be triaged moving forward.

April 19, 2023

Following their review of recent clinical data, expert panelists consider how neoadjuvant cemiplimab will fit into the real-world treatment paradigm of resectable CSCC, including the possibility of delaying or avoiding surgery in patients who have an adequate response to cemiplimab.

April 19, 2023

Nikhil Khushalani, MD, gives a comprehensive overview of cemiplimab and pembrolizumab for treating CSCC.